Cubist Corporate Development
Cubist Pharmaceuticals is a leader in the development and commercialization of acute care drugs for the treatment of unmet medical needs. With a proven track record of success in antibiotics, Cubist has the Clinical, Regulatory and Commercial capacity and expertise to acquire, develop and commercialize pharmaceutical products at any stage of research and development. The Business Development strategy focuses on novel therapeutics (including small molecules, proteins, and antibodies) at any stage of research or development that are consistent with the company's commercial strength in the hospital environment.
To discuss opportunities with Cubist Pharmaceuticals, the Business Development Team recommends that potential collaborators provide a detailed non-confidential package describing the opportunity, including supporting scientific data.
For discovery technologies and pre-clinical programs please send your inquiries to:
Christo Shalish
Director, Science & Technology Licensing
Christo.shalish@cubist.com
For clinical program in-licensing or out-licensing, please send your inquiries to:
bd@cubist.com
Tel: 781.860.8660 | Fax: 781.860.1194
or via mail
Business Development
Cubist Pharmaceuticals, Inc.
65 Hayden Avenue
Lexington, Massachusetts 02421
Who we are:
-
Mary Thistle, Vice President
-
Christo Shalish, Director
-
Steven Luperchio, Ph.D., Senior Manager
-
Aaron Pelta, Senior Director
-
Bradley Prosek, Senior Director
- Sarah Streisand, Coordinator